NDAORALTABLET
Approved
Jan 2013
Lifecycle
Peak
Competitive Pressure
15/100
Clinical Trials
2
Data completeness
5/8 — Partial
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KAZANO is a fixed-dose combination oral tablet containing alogliptin (a dipeptidyl peptidase-4 inhibitor) and metformin hydrochloride, indicated for type 2 diabetes mellitus. The combination works by enhancing insulin secretion and improving glucose utilization while reducing hepatic glucose production. It is designed as an adjunctive therapy for patients inadequately controlled on metformin monotherapy or alogliptin alone.
$0.112MPart D
Peak2.9 years to LOEProduct is in peak lifecycle stage with modest Part D spending (215 claims in 2023), indicating established but niche positioning within the competitive diabetes market.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Specified Drug-Use Survey of Alogliptin and Metformin Hydrochloride Combination Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Renal or Hepatic Impairment or Advanced Age"
Started Feb 2017
1,026 enrolled
Type 2 Diabetes Mellitus
Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan
Started Jan 2007
480 enrolled
Diabetes Mellitus, Type 2
Why This Matters for Your Career
Worked on KAZANO at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.